Skip to content
brief.finance
Get Willow

NASDAQ · Healthcare

Regeneron Pharmaceuticals, Inc. (REGN) stock research

Regeneron Pharmaceuticals, Inc. (REGN) is listed on NASDAQ. Regeneron Pharmaceuticals, Inc. reported revenue of $14.3B in the fiscal year that ended on 2025-12-31. Revenue rose 1% from the year before. Regeneron Pharmaceuticals, Inc.’s net income for that year was $4.5B. The SEC classifies it under Pharmaceutical Preparations. It is incorporated in New York. Its most recent SEC filing is Form 8-K (current report), filed on 2026-10-06.

Open REGN in Willow. Filings, fundamentals, recent news — sourced stock research, no recommendation.

Get Willow · Read methodology

Annual financials

As tagged by Regeneron Pharmaceuticals, Inc. in its annual reports on SEC EDGAR. The latest year is from Form 10-K, filed on 2026-02-04.

Regeneron Pharmaceuticals, Inc. (REGN) annual financials, in USD
Fiscal year endedRevenueNet incomeDiluted EPSCash and equivalents
2025-12-31$14.3B$4.5B$41.48$3.1B
2024-12-31$14.2B$4.4B$38.34$2.5B
2023-12-31$13.1B$4.0B$34.77$2.7B

Recent SEC filings

Filed with the SEC under CIK 0000872589. Every row is read from the filing itself on EDGAR, not from a summary of it.

  • 8-K (current report) filed 2026-10-06 · period ending 2026-10-01
  • 8-K (current report) filed 2026-09-30 · period ending 2026-09-24
  • 10-Q (quarterly report) filed 2026-07-30 · period ending 2026-06-30
  • 8-K (current report) filed 2026-07-30 · period ending 2026-07-30
  • 8-K (current report) filed 2026-07-06 · period ending 2026-07-06
  • 8-K (current report) filed 2026-06-17 · period ending 2026-06-12

Filing history read from SEC EDGAR on 2026-10-19.

What a Willow brief on REGN checks

  • Recent filings and company disclosures.
  • TTM fundamentals and valuation context.
  • Recent news and market context separated from primary filings.
  • Bull case, bear case, key risks, and watch-next items in a non-directional register.

Questions about REGN

What was Regeneron Pharmaceuticals, Inc.’s revenue in the fiscal year ended 2025-12-31?
$14.3B for the fiscal year that ended on 2025-12-31, as reported in Form 10-K filed on 2026-02-04.
Was Regeneron Pharmaceuticals, Inc. profitable in the fiscal year ended 2025-12-31?
Yes. It reported net income of $4.5B for the fiscal year that ended on 2025-12-31.
What were Regeneron Pharmaceuticals, Inc.’s diluted earnings per share in the fiscal year ended 2025-12-31?
$41.48 per diluted share for the fiscal year that ended on 2025-12-31.
How much cash did Regeneron Pharmaceuticals, Inc. hold at the end of the fiscal year ended 2025-12-31?
$3.1B in cash and cash equivalents on 2025-12-31.
What is Regeneron Pharmaceuticals, Inc.’s most recent SEC filing?
Form 8-K (current report), filed on 2026-10-06. brief.finance reads it directly from SEC EDGAR.
When does Regeneron Pharmaceuticals, Inc.’s fiscal year end?
Its SEC registration lists the year end as 31 December. The annual figures on this page cover the fiscal year that ended on 2025-12-31.
What is Regeneron Pharmaceuticals, Inc.’s SEC CIK number?
0000872589. EDGAR uses this Central Index Key to identify every filing the company submits.
What does a Willow brief on REGN include?
Recent SEC filings, fundamentals and valuation context, price history, and both a bull case and a bear case. Every figure links to the source it came from.
Does brief.finance say whether to buy or sell REGN?
No. brief.finance publishes educational research and does not recommend buying, selling, or holding any security.

Primary source paths

More Healthcare research hubs

Author and editorial responsibility

By Joseph, Founder and editor, brief.finance. Every brief is generated under a fixed editorial and compliance method operated by Reaktif LLC.

About the author · Disclosures · Stock Directory

Ticker catalog last updated 2026-10-19.